Evogliptin, a DPP-4 inhibitor, prevents diabetic cardiomyopathy by alleviating cardiac lipotoxicity in db/db mice

Dipeptidyl peptidase-4 (DPP-4) inhibitors are glucose-lowering drugs for type 2 diabetes mellitus (T2DM). We investigated whether evogliptin® (EVO), a DPP-4 inhibitor, could protect against diabetic cardiomyopathy (DCM) and the underlying mechanisms. Eight-week-old diabetic and obese db/db mice were...

Descripción completa

Detalles Bibliográficos
Autores principales: Pham, Trong Kha, Nguyen, To Hoai T., Yi, Joo Mi, Kim, Gwang Sil, Yun, Hyeong Rok, Kim, Hyoung Kyu, Won, Jong Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10167305/
https://www.ncbi.nlm.nih.gov/pubmed/37009790
http://dx.doi.org/10.1038/s12276-023-00958-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10167305/
https://www.ncbi.nlm.nih.gov/pubmed/37009790
http://dx.doi.org/10.1038/s12276-023-00958-6

Ejemplares similares